Attached files
| file | filename |
|---|---|
| EX-99.1 - PRESS RELEASE OF IMMUNOMEDICS, INC., DATED JANUARY 18, 2017, TITLED "IMMUNOMEDIC - IMMUNOMEDICS INC | f8k011817ex99i_immunomedics.htm |
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT
REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): January 18, 2017
Immunomedics, Inc.
(Exact Name of Registrant as Specified in its Charter)
| Delaware | 000-12104 | 61-1009366 | ||
| (State
or Other Jurisdiction of Incorporation) |
(Commission
File Number) |
(IRS
Employer Identification No.) |
| 300 The American Road, Morris Plains, New Jersey | 07950 | |
| (Address of principal executive offices) | (Zip Code) |
(973)
605-8200
(Registrant’s telephone number, including area code)
Not
applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 7.01. Regulation FD Disclosure.
On January 18, 2017, Immunomedics, Inc. issued a press release titled “Immunomedics Highlights Expanded Pipeline Positioning Company for Sustained Value Creation.” The full text of the press release is attached to this current report on Form 8-K as Exhibit 99.1 and is incorporated by reference herein.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
| Exhibit No. | Description of Exhibit | |
| 99.1 | Press Release of Immunomedics, Inc., dated January 18, 2017, titled “Immunomedics Highlights Expanded Pipeline Positioning Company for Sustained Value Creation.” |
| 2 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| IMMUNOMEDICS, INC. | ||
| By: | /s/ Michael R. Garone | |
| Name: | Michael R. Garone | |
| Title: | Vice President, Finance and Chief Financial Officer | |
| Date: January 18, 2017 | ||
| 3 |
Exhibit Index
| Exhibit No. | Description of Exhibit | |
| 99.1 | Press Release of Immunomedics, Inc., dated January 18, 2017, titled “Immunomedics Highlights Expanded Pipeline Positioning Company for Sustained Value Creation.” |
4